Costs of glaucoma medications

American Journal of Health-System Pharmacy

Volumn 55, Issue 3, 1998, Pages 272-275

  Fiscella, Richard G ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; PROSTAGLANDIN;

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; DRUG COST; DRUG MARKETING; GLAUCOMA; HEALTH CARE COST; INTRAOCULAR HYPERTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 0032005245     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.3.272     Document Type: Article

References (20)

1. Glaucoma Panel. Primary open angle glaucoma suspect: preferred practice pattern. San Francisco: American Academy of Ophthalmology; 1995:4-6.
2. Quigley HA, Number of people with glaucoma worldwide. Br J Ophthalmol. 1996; 80:389-93.
3. Consensus Panel on Open Angle Glaucoma. Care of the patient with open angle glaucoma: optometric clinical practice guideline. St. Louis: American Optometric Association; 1995:3-10.
4. Ritch R, Shields MB, Krupin T. Chronic open-angle glaucoma: treatment overview. In: Ritch R, Shields MB, Krupin T, eds. The glaucomas. 2nd ed. St. Louis: Mosby; 1996:1507-19.
5. Zimmerman T. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol. 1983; 289(suppl):252-7.
6. Cardinle V. Drug Topics red book. Montvale, NJ: Medical Economics; 1996.
7. Serle JB. Pharmacological advances in the treatment of glaucoma. Drugs Aging. 1994; 5:156-70.
8. Novack GD, Robin AL, Derick RJ. New medical treatments for glaucoma. Int Ophthalmol Clin. 1993; 33:183-202.
9. Monane M, Bonn RL, Gurwitz JH et al. Topical glaucoma medications and cardiovascular risk in the elderly. Clin Pharmacol Ther. 1994; 55(1):76-83.
10. Fraunfeder FT, Meyer SM. Systemic adverse reactions to glaucoma medications. Int Ophthalmol Clin. 1989; 29:1143-6.
11. O'Donoghue E. Beta-blockers and the elderly with glaucoma: are we adding insult to injury? Br J Ophthalmol. 1995; 79:794-6.
12. Donohue EK, Wilensky JT. Trusopt, a topical carbonic anhydrase inhibitor. J Glaucoma. 1996; 5:68-74.
13. Schuman JS, Horwitz B, Choplin NT et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Arch Ophthalmol. 1997; 115:847-52.
14. Wilensky J. The role of brimonidine in the treatment of open-angle glaucoma. Surv Ophthalmol. 1996; 41(suppl 1):S3-7.
15. Camras CB and the U.S.A. Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Ophthalmology. 1996; 103:138-47.
16. Watson P, Stjernschantz J, and the U.S.A. Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996; 103:126-37.
17. Weiss MA, Hendrickson JR. Information on drop size needs to be eyed closely. Am J Hosp Pharm. 1994; 51:2969-70. Letter.
18. Ball SF, Schneider E. Cost of beta-adrenergic receptor blocking agents for ocular hypertension. Arch Ophthalmol. 1992; 110:654-7.
19. Hartnbaum D, Stek M, Haggert B et al. Quantitative and cost evaluation of three antiglaucoma beta-blocker agents: Timoptic-XE versus two generic levobunolol products. Am J Manag Care. 1996; 2:157-62.
20. Schwartz J, Christensen RE, Lee DA. Comparison of timolol maleate and levobunolol: doses and volume per bottle. Arch Ophthalmol. 1989; 107:17. Letter.